

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM819103

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
PEAR THERAPEUTICS (US), INC.		06/16/2023	Corporation: DELAWARE
PEAR THERAPEUTICS, INC.		06/16/2023	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	HARVEST BIO LLC		
Street Address:	135 SEAPORT BLVD., UNIT 1106		
City:	Boston		
State/Country:	MASSACHUSETTS		
Postal Code:	02210		
Entity Type:	Limited Liability Company: DELAWARE		
PROPERTY NUMBERS Total: 7			
Property Type	Number	Word Mark	
Serial Number:	86802103	RESET	
Serial Number:	87925158	RESET	
Serial Number:	87925174	RESET	
Serial Number:	97139698	RESET-A	
Serial Number:	87635226	RESET-O	
Serial Number:	87925200	RESET-O	
Serial Number:	87925189	RESET-O	
CORRESPONDENCE DATA			
Fax Number:	4153742399		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	4153742300		
Email:	teri.nelmark@hoganlovells.com		
Correspondent Name:	HOGAN LOVELL US LLP		
Address Line 1:	Four Embarcadero Center, Suite 3500		
Address Line 4:	San Francisco, CALIFORNIA 94111		
NAME OF SUBMITTER:	JASON LOHR		
SIGNATURE:	/Jason Lohr/		

CH \$190.00 86802103

DATE SIGNED:

06/22/2023

Total Attachments: 19

source=Pear - Harvest Bio - IP Assignment Agreement#page1.tif
source=Pear - Harvest Bio - IP Assignment Agreement#page2.tif
source=Pear - Harvest Bio - IP Assignment Agreement#page3.tif
source=Pear - Harvest Bio - IP Assignment Agreement#page4.tif
source=Pear - Harvest Bio - IP Assignment Agreement#page5.tif
source=Pear - Harvest Bio - IP Assignment Agreement#page6.tif
source=Pear - Harvest Bio - IP Assignment Agreement#page7.tif
source=Pear - Harvest Bio - IP Assignment Agreement#page8.tif
source=Pear - Harvest Bio - IP Assignment Agreement#page9.tif
source=Pear - Harvest Bio - IP Assignment Agreement#page10.tif
source=Pear - Harvest Bio - IP Assignment Agreement#page11.tif
source=Pear - Harvest Bio - IP Assignment Agreement#page12.tif
source=Pear - Harvest Bio - IP Assignment Agreement#page13.tif
source=Pear - Harvest Bio - IP Assignment Agreement#page14.tif
source=Pear - Harvest Bio - IP Assignment Agreement#page15.tif
source=Pear - Harvest Bio - IP Assignment Agreement#page16.tif
source=Pear - Harvest Bio - IP Assignment Agreement#page17.tif
source=Pear - Harvest Bio - IP Assignment Agreement#page18.tif
source=Pear - Harvest Bio - IP Assignment Agreement#page19.tif

INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT

This Intellectual Property Assignment Agreement (this “Assignment”) is effective as of June 16, 2023, and is made and entered into between PEAR THERAPEUTICS (US), INC., a Delaware corporation (“Pear Therapeutics (US)”) and PEAR THERAPEUTICS, INC., a Delaware corporation which owns 100% of the issued and outstanding capital stock of Pear Therapeutics US (“Parent”; Parent together with Pear Therapeutics (US), the “Assignor”), and HARVEST BIO LLC, a Delaware limited liability company (“Assignee”), pursuant to the Asset Purchase Agreement dated as of May 21, 2023 (the “Purchase Agreement”), by and among the Assignor and Assignee. Capitalized terms used in this Assignment without definition shall have the respective meanings given to them in the Purchase Agreement, and Section 9.6(a) of the Purchase Agreement (Certain Interpretations) applies to this Assignment.

For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and as more fully set forth in the Purchase Agreement and subject to the terms and conditions therein, Assignor and Assignee agree as follows:

1. Assignor hereby irrevocably assigns, transfers and conveys to Assignee, any and all of its right, title and interest in and to all Seller Owned Intellectual Property, including each item of Intellectual Property set forth on Schedule A hereto, held or used in the conduct of, or which in any way, directly or indirectly, comprise or relate to, or are necessary or useful for the further research, development and commercialization of, the Business related to the Acquired Assets, including all goodwill appurtenant thereto, all rights therein provided by international conventions and treaties, all rights of priority and renewals, and all rights to sue and recover damages for past, present and future infringement, dilution, misappropriation or other violation thereof, whether such rights are registered or not, and all rights of priority therein, and the right to recover for damages and profits and all other remedies for past infringements thereof, and any and all appurtenant goodwill associated therewith, but excluding any Excluded Assets. In accordance with Section 2.8 of the Purchase Agreement, the Intellectual Property included in the Acquired Assets shall include:

(a) the Intellectual Property set forth on Exhibit A to the Purchase Agreement and all other Intellectual Property related to or used in connection with any Acquired Assets, plus:

(b) all reissues, reexaminations, divisions, renewals, extensions, provisionals, continuations, continuations-in-part, and domestic and foreign counterparts of any of the patents or patent applications described in clause “(a)” above, all other patents and patent applications that derive or may derive a claim of priority from any of the patents or patent applications described in clause “(a)” above, and each patent issuing on any of the foregoing;

(c) each patent and patent application that is referenced by a terminal disclaimer filed in connection with any of the patents or patent applications identified in clause “(a)” or clause “(b)” above;

(d) all subject matter, and each invention, claimed or disclosed in each of the patents and patent applications described in “(a)”, “(b)”, or “(c)” above;

(e) all rights to apply in any and all jurisdictions anywhere in the world for patents, certificates of inventions, utility models, or other governmental grants with respect to each patent, patent application, and invention described above, including the right to apply for patents pursuant to any convention, treaty, agreement or understanding; and

(f) any and all causes of action (whether known or unknown or whether currently pending, filed, or otherwise) and other enforcement rights under, or on account of, any of the foregoing Intellectual Property, including all causes of action and other enforcement rights for (1) damages, (2) injunctive relief, (3) any other remedies of any kind (in each of the cases in clauses “(1)”, “(2)”, and “(3)” of this paragraph for past, current, and future infringement), and (4) all rights to collect royalties and other payments under or on account of each of the foregoing Intellectual Property.

2. Upon and at any time after the Closing, at Assignee’s request, Assignor shall, without further consideration, execute and deliver to Assignee such other instruments and documents, and take such other actions as Assignee may reasonably deem necessary or desirable to effect, evidence, record and perfect the transfer and assignment contemplated by this Assignment. In the event that Assignor fails to execute and deliver such instruments and documents, Assignor hereby authorizes and appoints Assignee and Assignee’s authorized representatives as Assignor’s true and lawful attorney in fact solely for the purposes of executing and delivering such instruments and documents on behalf of and in the name of Assignor as to effect, evidence or perfect the transfer and assignment of the Acquired Assets to Assignee, including any filings with the United States Patent and Trademark Office, United States Copyright Office or any similar or corresponding entities or agencies in all other jurisdictions.

3. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns.

4. This Agreement shall be governed by, interpreted under, and construed and enforceable in accordance with, the laws of the State of Delaware, without regard to its conflict of law principle provisions and rules.

5. To the extent this Agreement is inconsistent with any terms or conditions in the Purchase Agreement, the Purchase Agreement shall control.

6. This Agreement may be executed in counterpart signature pages, all of which when so executed and attached hereto shall constitute one and the same original.

[Signature pages follow.]

IN WITNESS WHEREOF, the parties hereto have executed this Intellectual Property Assignment Agreement as of the date first set forth above.

ASSIGNOR:

PEAR THERAPEUTICS (US), INC.

DocuSigned by:
By: Christopher D. T. Guiffre
Name: Christopher D. T. Guiffre
Title: Chief Financial Officer & Chief Operating Officer


PEAR THERAPEUTICS, INC.

DocuSigned by:
By: Christopher D. T. Guiffre
Name: Christopher D. T. Guiffre
Title: Chief Financial Officer & Chief Operating Officer

IN WITNESS WHEREOF, the parties hereto have executed this Intellectual Property Assignment Agreement as of the date first set forth above.

ASSIGNEE:

HARVEST BIO LLC

DocuSigned by:
By: 
Name: Corey McCann
Title: Manager

Schedule A
Patents

Domestic & Foreign Patents	Owner	Title	Patent #	Serial #	Status	Country/ID	Type	Filed Date	Publication #	Issue Date
Schizophrenia	Pearl21 + NIBR	Electronic Devices and Methods for Treatment Utilizing Antipsychotics in Combination with Digital Therapies		2,019BE +11	PUBLISHED	CN	UTL	6/21/2019	113397644	
Schizophrenia	Pearl11 + NIBR	Electronic Devices and Methods for Treatment Utilizing Antipsychotics in Combination with Digital Therapies		PCT/US2019/039846	NAT PHASE	WO	UTL	6/21/2019		
Schizophrenia	Pearl12 + NIBR	Electronic Devices and Methods for Treatment Utilizing Antipsychotics in Combination with Digital Therapies		2019374695	PENDING	AU	UTL	6/21/2019		
Schizophrenia	Pearl14 + NIBR	Electronic Devices and Methods for Treatment Utilizing Antipsychotics in Combination with Digital Therapies		3118712	PENDING	CA	UTL	6/21/2019		
Schizophrenia	Pearl15 + NIBR	Electronic Devices and Methods for Treatment Utilizing Antipsychotics in Combination with Digital Therapies		197401326	PUBLISHED	EP	UTL	6/21/2019	3877982	
Schizophrenia	Pearl16 + NIBR	Electronic Devices and Methods for Treatment Utilizing Antipsychotics in Combination with Digital Therapies		2021-525324	PENDING	JP	UTL	6/21/2019		
Schizophrenia	Pearl17 + NIBR	Electronic Devices and Methods for Treatment Utilizing Antipsychotics in Combination with Digital Therapies		282965	PUBLISHED	IL	UTL	6/21/2019	44348	
Schizophrenia	Pearl18 + NIBR	Electronic Devices and Methods for Treatment Utilizing Antipsychotics in Combination with Digital Therapies		10-2021-7017059	PUBLISHED	KR	UTL	6/21/2019	10-2021-0111750	
Schizophrenia	Pearl19 + NIBR	Electronic Devices and Methods for Treatment Utilizing Antipsychotics in Combination with Digital Therapies		776081	PENDING	NZ	UTL	6/21/2019		
Schizophrenia	Pearl20 + NIBR	Electronic Devices and Methods for Treatment Utilizing Antipsychotics in Combination with Digital Therapies		11202104754P	PENDING	SG	UTL	6/21/2019		
Schizophrenia	Pearl21 + NIBR	Electronic Devices and Methods for Treatment Utilizing Antipsychotics in Combination with Digital Therapies		62/757,077	EXPIRED	US	PRV	11/7/2018		
Schizophrenia	Pearl24 + NIBR	Antipsychotics in Combination with Digital Therapies		16/448,907	PUBLISHED	US	UTL	6/21/2019	20200143931	
[21 Patent is jointly owned with NIBR. Purchaser will receive Pearl's interest in patent to be jointly owned with NIBR.										
[11 Patent is jointly owned with NIBR. Purchaser will receive Pearl's interest in patent to be jointly owned with NIBR.										
[21 Patent is jointly owned with NIBR. Purchaser will receive Pearl's interest in patent to be jointly owned with NIBR.										
[41 Patent is jointly owned with NIBR. Purchaser will receive Pearl's interest in patent to be jointly owned with NIBR.										
[51 Patent is jointly owned with NIBR. Purchaser will receive Pearl's interest in patent to be jointly owned with NIBR.										
[61 Patent is jointly owned with NIBR. Purchaser will receive Pearl's interest in patent to be jointly owned with NIBR.										
[71 Patent is jointly owned with NIBR. Purchaser will receive Pearl's interest in patent to be jointly owned with NIBR.										
[81 Patent is jointly owned with NIBR. Purchaser will receive Pearl's interest in patent to be jointly owned with NIBR.										
[91 Patent is jointly owned with NIBR. Purchaser will receive Pearl's interest in patent to be jointly owned with NIBR.										
[20 Patent is jointly owned with NIBR. Purchaser will receive Pearl's interest in patent to be jointly owned with NIBR.										
[21 Patent is jointly owned with NIBR. Purchaser will receive Pearl's interest in patent to be jointly owned with NIBR.										

Domestic & Foreign Patents

Indication	Owner	Title	Patent #	Serial #	Status	Country ID	Type	Filed Date	Publication #
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Sclerosis		62/835,250	EXPIRED	US	PRV	4/17/2019	
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Sclerosis		2020257885	PENDING	AU	UTL	4/13/2020	
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Sclerosis		3136946	PENDING	CA	UTL	4/13/2020	
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Sclerosis		202080038804	PUBLISHED	CN	UTL	4/13/2020	113892147
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Sclerosis		PA 2019 70328	ABANDONED	DK	UTL	5/24/2019	PA 2019 70328
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Sclerosis		20723703	PUBLISHED	EP	UTL	4/13/2020	3956895
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Sclerosis		PCT/US2020/027919	NAT PHASE	WO	UTL	4/13/2020	2020214523
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Sclerosis		16/047 043	PUBLISHED	US	UTL	4/13/2020	20200330019
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Sclerosis		286965	PENDING	IL	UTL	4/13/2020	
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Sclerosis		2021-561930	PUBLISHED	JP	UTL	4/13/2020	
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Sclerosis		10-2021-7035667	PUBLISHED	KR	UTL	4/13/2020	10-2022-0099842
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Sclerosis		781049	PENDING	NZ	UTL	4/13/2020	
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Sclerosis		1120211418X	PENDING	SG	UTL	4/13/2020	
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Sclerosis		3136943	PENDING	CA	UTL	4/13/2020	
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Sclerosis		202080038801	PUBLISHED	CN	UTL	4/13/2020	114303204
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Sclerosis		PA 2019 70330	ABANDONED	DK	UTL	5/24/2019	DK 2019 70328
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Sclerosis		20722290	PUBLISHED	EP	UTL	4/13/2020	3956899
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Sclerosis		286964	PENDING	IL	UTL	4/13/2020	
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Sclerosis		2021-561931	PUBLISHED	JP	UTL	4/13/2020	2022-5296474
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Sclerosis		10-2021-7035660	PUBLISHED	KR	UTL	4/13/2020	10-2022-0011118
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Sclerosis		781057	PENDING	NZ	UTL	4/13/2020	
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Sclerosis		1120211417U	PENDING	SG	UTL	4/13/2020	
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Sclerosis		2020260080	PENDING	AU	UTL	4/13/2020	
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Sclerosis		PCT/US2020/027892	NAT PHASE	WO	UTL	4/13/2020	2020214513
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Sclerosis		62/835,295	EXPIRED	US	PRV	4/17/2019	
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Sclerosis		16/046 996	PUBLISHED	US	UTL	4/13/2020	20200335191

111 Patent is jointly owned with MSRI. Patentee will receive Pear's interest in patent to be jointly owned with MSRI.
 112 Patent is jointly owned with MSRI. Patentee will receive Pear's interest in patent to be jointly owned with MSRI.
 113 Patent is jointly owned with MSRI. Patentee will receive Pear's interest in patent to be jointly owned with MSRI.
 114 Patent is jointly owned with MSRI. Patentee will receive Pear's interest in patent to be jointly owned with MSRI.
 115 Patent is jointly owned with MSRI. Patentee will receive Pear's interest in patent to be jointly owned with MSRI.
 116 Patent is jointly owned with MSRI. Patentee will receive Pear's interest in patent to be jointly owned with MSRI.
 117 Patent is jointly owned with MSRI. Patentee will receive Pear's interest in patent to be jointly owned with MSRI.
 118 Patent is jointly owned with MSRI. Patentee will receive Pear's interest in patent to be jointly owned with MSRI.
 119 Patent is jointly owned with MSRI. Patentee will receive Pear's interest in patent to be jointly owned with MSRI.
 120 Patent is jointly owned with MSRI. Patentee will receive Pear's interest in patent to be jointly owned with MSRI.
 121 Patent is jointly owned with MSRI. Patentee will receive Pear's interest in patent to be jointly owned with MSRI.
 122 Patent is jointly owned with MSRI. Patentee will receive Pear's interest in patent to be jointly owned with MSRI.
 123 Patent is jointly owned with MSRI. Patentee will receive Pear's interest in patent to be jointly owned with MSRI.
 124 Patent is jointly owned with MSRI. Patentee will receive Pear's interest in patent to be jointly owned with MSRI.
 125 Patent is jointly owned with MSRI. Patentee will receive Pear's interest in patent to be jointly owned with MSRI.

Domestic & Foreign Patents

<u>Owner</u>	<u>Title</u>	<u>Patent #</u>	<u>Serial #</u>	<u>Status</u>	<u>Country ID</u>	<u>Type</u>	<u>Filed Date</u>	<u>Publication #</u>	<u>Issue Date</u>
Pear	Display Screen or Portion Thereof With an Animated Graphical User Interface	D880,498	29/665,681	ISSUED	US	DES	10/5/2018		4/7/2020
Pear	DISPLAY SCREEN OR PORTION THEREOF WITH A GRAPHICAL USER INTERFACE	D899,438	29/665,670	ISSUED	US	DES	10/5/2018		10/20/2020
	Formerly: Graphical User Interface								
	Therapy Lessons								
Pear	Filed as: Display Screen or Portion Thereof with an Animated Graphical User Interface	D917,501	29/665,666	ISSUED	US	DES	10/5/2018		4/27/2021
Pear	Report Your Status Filed as: Graphical User Interface		29/665,673	ABANDONED	US	DES	10/5/2018		
Pear	A Digital Therapeutic Component to Optimize Buprenorphine Induction		62/779,705	EXPIRED	US	PRV	12/1/2018		
Pear	A Digital Therapeutic Component to Optimize Induction of Buprenorphine-Containing Products		2019396627	PENDING	AU	UTL	12/1/6/2019		
Pear	A Digital Therapeutic Component to Optimize Induction of Buprenorphine-Containing Products		3122430	PENDING	CA	UTL	12/1/6/2019		
Pear	A Digital Therapeutic Component to Optimize Induction of Buprenorphine-Containing Products		201980091821	PUBLISHED	CN	UTL	12/1/6/2019	113811950	
Pear	The Ornamental Design for a Display Screen or Portion thereof with an Animated Graphic User Interface	006369658-0001	006369658-0001	ISSUED	EU	DES	4/4/2019		4/4/2019
Pear	Ornamental Design for a Display Screen or Portion Thereof with a Graphical User Interface	006369658-0002	006369658-0002	ISSUED	EU	DES	4/4/2019		4/4/2019
Pear	Ornamental Design for a Display Screen or Portion Thereof with a Graphical User Interface	006369658-0003	006369658-0003	ISSUED	EU	DES	4/4/2019		4/4/2019
Pear	Ornamental Design for a Display Screen or Portion Thereof with a Graphical User Interface	006369658-0004	006369658-0004	ISSUED	EU	DES	4/4/2019		4/4/2019
Pear	The Ornamental Design for a Display Screen or Portion thereof with an Animated Graphic User Interface	90063696580001	90063696580001	ISSUED	GB	DES	4/4/2019		4/4/2019
Pear	Ornamental Design for a Display Screen or Portion Thereof with a Graphical User Interface	90063696580002	90063696580002	ISSUED	GB	DES	4/4/2019		4/4/2019
Pear	Ornamental Design for a Display Screen or Portion Thereof with a Graphical User Interface	90063696580003	90063696580003	ISSUED	GB	DES	4/4/2019		4/4/2019
Pear	Ornamental Design for a Display Screen or Portion Thereof with a Graphical User Interface	90063696580004	90063696580004	ISSUED	GB	DES	4/4/2019		4/4/2019
Pear	A Digital Therapeutic Component to Optimize Induction of Buprenorphine-Containing Products		PCT/US2019/066509	NAT PHASE	WO	UTL	12/1/6/2019	2020124073	
Pear	A Digital Therapeutic Component to Optimize Induction of Buprenorphine-Containing Products		19895058.6	PUBLISHED	EP	UTL	12/1/6/2019	3895173	

Pear	Digital Therapeutic Component to Optimize Induction of Buprenorphine-Containing Products	16715,680	PUBLISHED	US	UTL	12/16/2019	20200187777
Pear	A Digital Therapeutic Component to Optimize Induction of Buprenorphine-Containing Products	283747	PENDING	IL	UTL	12/16/2019	
Pear	A Digital Therapeutic Component to Optimize Induction of Buprenorphine-Containing Products	2021-533336	PENDING	JP	UTL	12/16/2019	
Pear	A Digital Therapeutic Component to Optimize Induction of Buprenorphine-Containing Products	10-2021-7020286	PUBLISHED	KR	UTL	12/16/2019	10-2021-0114940
Pear	A Digital Therapeutic Component to Optimize Induction of Buprenorphine-Containing Products	777482	PENDING	NZ	UTL	12/16/2019	
Pear	A Digital Therapeutic Component to Optimize Induction of Buprenorphine-Containing Products	11202106207V	PENDING	SG	UTL	12/16/2019	

Trademarks

Corporate Trademarks

COUNTRY	MARK	APP. NO.	REG. NO.	STATUS	GOODS/SERVICES	FILE DATE	REG DATE
United States of America	EFORMULATION	97372560		Published (5/16/23)	09 - Downloadable software for collecting data on a patient's use of and subjective experience with pharmaceuticals, nutritional supplements, or medical foods; Downloadable software for guiding a patient's use of pharmaceuticals, nutritional supplements, or medical foods; Downloadable software for monitoring and improving the efficacy of pharmaceuticals, nutritional supplements, or medical foods; Downloadable software for monitoring and improving the side effects of pharmaceuticals, nutritional supplements, or medical foods; Downloadable software for collecting biometric data from patients; Downloadable software for the treatment of diseases and disorders	4/20/2022	
United States of America	Pear Logo	87289058	5404618	Registered	05 - nutritional supplements	1/4/2017	2/20/2018
United States of America	Pear Logo	87289058	5404618	Registered	09 - Software for collecting data on a patient's use of and subjective experience with nutritional supplements; software for guiding a patient's use of nutritional supplements; software for monitoring and improving the efficacy of nutritional supplements; software for monitoring and improving the side effects of nutritional supplements; software for collecting biometric data from patients	1/4/2017	2/20/2018
United States of America	Pear Logo	87289058	5404618	Registered	42 - software development in the fields of healthcare, therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for monitoring, reporting on, and analyzing the use of therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for healthcare providers and patients to communicate regarding healthcare and the use of therapeutics; pharmaceuticals, and nutritional supplements	1/4/2017	2/20/2018
United States of America	Pear Therapeutics	87289040	5399391	Registered	09 - Software for collecting data on a patient's use of and subjective experience with nutritional supplements; software for guiding a patient's use of nutritional supplements; software for monitoring and improving the efficacy of nutritional supplements; software for monitoring and improving the side effects of nutritional supplements; software for collecting biometric data from patients	1/4/2017	2/13/2018

United States of America	PEAR THERAPEUTICS	87289040	5399391	Registered	42 - software development in the fields of healthcare, therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for monitoring, reporting on, and analyzing the use of therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for healthcare providers and patients to communicate regarding healthcare and the use of therapeutics; pharmaceuticals, and nutritional supplements	1/4/2017	2/13/2018
AUSTRALIA	PEAR THERAPEUTICS	1685744	1686230	REGISTERED	09 - Software for collecting data on a patient's use of and subjective experience with nutritional supplements; software for guiding a patient's use of nutritional supplements; software for monitoring and improving the efficacy of nutritional supplements; software for monitoring and improving the side effects of nutritional supplements; software for collecting biometric data from patients	8/18/2022	8/18/2022
(WIPO)					42 - software development in the fields of healthcare, therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for monitoring, reporting on, and analyzing the use of therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for healthcare providers and patients to communicate regarding healthcare and the use of therapeutics; pharmaceuticals, and nutritional supplements		
CANADA	PEAR THERAPEUTICS	1685744		PENDING - Under examination	09 - Software for collecting data on a patient's use of and subjective experience with nutritional supplements; software for guiding a patient's use of nutritional supplements; software for monitoring and improving the efficacy of nutritional supplements; software for monitoring and improving the side effects of nutritional supplements; software for collecting biometric data from patients	8/18/2022	
(WIPO)					42 - software development in the fields of healthcare, therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for monitoring, reporting on, and analyzing the use of therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for healthcare providers and patients to communicate regarding healthcare and the use of therapeutics; pharmaceuticals, and nutritional supplements		

CHINA	PEAR THERAPEUTICS	67590987		1/29/23 response filed: supplemental evidence due April 29, 2023.	09 - 1. computer software, recorded; 2. computer software applications, downloadable; 3. software as a medical device [SaMD], downloadable; 4. data processing apparatus; 5. Smartphone software applications, downloadable; 6. biometric identity cards; 7. Computer programs, downloadable; 8. Computer software for processing digital images; 9. Central processor for processing information, data, sound and images; 10. Software for radiation dose measurement in the field of radiotherapy	10/8/2022	
CHINA	PEAR THERAPEUTICS	67589216		1/29/23 response filed: supplemental evidence due April 29, 2023.	42 - 1. medical research; 2. research and development of new products for others; 3. scientific research; 4. software as a service [SaS]; 5. computer software design; 6. Computer software installation, maintenance and repair; 7. Mobile phone software design; 8. electronic data storage; 9. Medical computer programming; 10. Computer software research and development	10/8/2022	
CHINA	PEAR THERAPEUTICS (refile)	69383448		PENDING - Under examination	42 - Clinical trials; Medical laboratory service; Medical research; Scientific research; Research and development of new products for others; Software as a service (Saas); Computer software installation, maintenance and repair; Mobile phone software design; Electronic data storage; Medical computer programming; Computer software research and development; Computer software design.	2/3/2023	
EUROPEAN UNION (EUTM & RCD)	PEAR THERAPEUTICS	1685744	1685744	REGISTERED	09 - Software for collecting data on a patient's use of and subjective experience with nutritional supplements; software for guiding a patient's use of nutritional supplements; software for monitoring and improving the efficacy of nutritional supplements; software for monitoring and improving the side effects of nutritional supplements; software for collecting biometric data from patients	8/18/2022	8/18/2023
(WIPO)					42 - software development in the fields of healthcare, therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for monitoring, reporting on, and analyzing the use of therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for healthcare providers and patients to communicate regarding healthcare and the use of therapeutics; pharmaceuticals, and nutritional supplements		
ISRAEL (WIPO)	PEAR THERAPEUTICS	1685744		Published for opposition: opposition period ends June 1, 2023	09 - Software for collecting data on a patient's use of and subjective experience with nutritional supplements; software for guiding a patient's use of nutritional supplements; software for monitoring and improving the efficacy of nutritional supplements; software for monitoring and improving the side effects of nutritional supplements; software for collecting biometric data from patients	8/18/2022	

					42 - software development in the fields of healthcare, therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for monitoring, reporting on, and analyzing the use of therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for healthcare providers and patients to communicate regarding healthcare and the use of therapeutics, pharmaceuticals, and nutritional supplements		
JAPAN (WIPO)	PEAR THERAPEUTICS	1685744		PENDING - Under examination	09 - Software for collecting data on a patient's use of and subjective experience with nutritional supplements; software for guiding a patient's use of nutritional supplements; software for monitoring and improving the efficacy of nutritional supplements; software for monitoring and improving the side effects of nutritional supplements; software for collecting biometric data from patients	8/18/2022	
NEW ZEALAND (WIPO)	PEAR THERAPEUTICS	1685744	1685744	REGISTERED	09 - Software for collecting data on a patient's use of and subjective experience with nutritional supplements; software for guiding a patient's use of nutritional supplements; software for monitoring and improving the efficacy of nutritional supplements; software for monitoring and improving the side effects of nutritional supplements; software for collecting biometric data from patients	8/18/2022	8/18/2022
SINGAPORE (WIPO)	PEAR THERAPEUTICS	1685744		PENDING - Under examination	09 - Software for collecting data on a patient's use of and subjective experience with nutritional supplements; software for guiding a patient's use of nutritional supplements; software for monitoring and improving the efficacy of nutritional supplements; software for monitoring and improving the side effects of nutritional supplements; software for collecting biometric data from patients	8/18/2022	

					42 - software development in the fields of healthcare, therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for monitoring, reporting on, and analyzing the use of therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for healthcare providers and patients to communicate regarding healthcare and the use of therapeutics, pharmaceuticals, and nutritional supplements		
SOUTH KOREA	PEAR THERAPEUTICS	1685744		PENDING - Under examination	09 - Software for collecting data on a patient's use of and subjective experience with nutritional supplements; software for guiding a patient's use of nutritional supplements; software for monitoring and improving the efficacy of nutritional supplements; software for monitoring and improving the side effects of nutritional supplements; software for collecting biometric data from patients	8/18/2022	
(WIPO)					42 - software development in the fields of healthcare, therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for monitoring, reporting on, and analyzing the use of therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for healthcare providers and patients to communicate regarding healthcare and the use of therapeutics, pharmaceuticals, and nutritional supplements		
UNITED KINGDOM	PEAR THERAPEUTICS	1685744	1685744	REGISTERED	09 - Software for collecting data on a patient's use of and subjective experience with nutritional supplements; software for guiding a patient's use of nutritional supplements; software for monitoring and improving the efficacy of nutritional supplements; software for monitoring and improving the side effects of nutritional supplements; software for collecting biometric data from patients	8/18/2022	8/18/2022
(WIPO)					42 - software development in the fields of healthcare, therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for monitoring, reporting on, and analyzing the use of therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for healthcare providers and patients to communicate regarding healthcare and the use of therapeutics, pharmaceuticals, and nutritional supplements		

WIPO designating Australia, Canada, EU, UK, Israel, Japan, S. Korea, New Zealand and Singapore	PEAR THERAPEUTICS	1685744	1685744	Registered with International Bureau as of August 18, 2022. Application is now under examination in the designated countries noted above.	09 - Software for collecting data on a patient's use of and subjective experience with nutritional supplements; software for guiding a patient's use of nutritional supplements; software for monitoring and improving the efficacy of nutritional supplements; software for monitoring and improving the side effects of nutritional supplements; software for collecting biometric data from patients	8/18/2022	8/18/2022
--	----------------------	---------	---------	--	---	-----------	-----------

Trademarks

<u>COUNTRY</u>	<u>GOODS/SERVICES</u>	<u>MARK</u>	<u>APP. NO.</u>	<u>CLASS</u>	<u>REG. NO.</u>	<u>FILE DATE</u>	<u>REG DATE</u>	<u>STATUS</u>
USA	software for the treatment of substance use disorder	RESET	86802103	9	5138595	10/29/2015	2/7/2017	Registered
USA	software as a service (SAAS) services featuring software for the treatment of substance use disorder; namely, software for healthcare providers to access and analyze information and data from and to provide information and therapy to patients with substance use disorder	RESET	87925158	42	6190252	5/17/2018	11/3/2020	Registered
USA	software for the treatment of substance use disorder; namely, software for collecting information and data from and for delivering information and therapy to patients with substance use disorder	RESET Logo	87925174	9		5/17/2018		Opposed
USA	software as a service (SAAS) services featuring software for the treatment of substance use disorder; namely, software for healthcare providers to access and analyze information and data from and to provide information and therapy to patients with substance use disorder	RESET Logo	87925174	42		5/17/2018		Opposed
USA	software for the treatment of alcohol use disorder; namely, software for collecting information and data from and for delivering information and therapy to patients with alcohol use disorder	RESET-A	97139698	9		11/23/2021		Pending (Opposed)
USA	software as a service (SAAS) services featuring software for the treatment of alcohol use disorder; namely, software for healthcare providers to access and analyze information and data from and to provide information and therapy to patients with alcohol use disorder	RESET-A	97139698	42		11/23/2021		Pending (Opposed)
USA	software for the treatment of opioid use disorder; namely, software for collecting information and data from and for delivering information and therapy to patients with opioid use disorder	RESET-O	87635226	9	5740689	10/5/2017	4/20/2019	Registered (cancellation denied; under appeal)
USA	software as a service (SAAS) services featuring software for the treatment of opioid use disorder; namely, software for healthcare providers to access and analyze information and data from and to provide information and therapy to patients with opioid use disorder	RESET-O	87925290	42		5/17/2018		Opposed
USA	software for the treatment of opioid use disorder; namely, software for collecting information and data from and for delivering information and therapy to patients with opioid use disorder	RESET-O Logo	87925189	9		5/17/2018		Opposed
USA	software as a service (SAAS) services featuring software for the treatment of opioid use disorder; namely, software for healthcare providers to access and analyze information and data from and to provide information and therapy to patients with opioid use disorder	RESET-O Logo	87925189	42		5/17/2018		Opposed

Copyrights

Name	Full Title	Copyright Number	Date
Pear Therapeutics, Inc.	Pear-004.	TX0008935636	2020

Copyrights

Name	Full Title	Copyright Number	Date
Pear Therapeutics, Inc.	RESET 1.7.0 and RESET-O 1.3.0	TX0008825251	2019
Pear Therapeutics, Inc.	RESET 1.7.0 and RESET-O 1.3.0 & 2 other titles	V9978D306	
Pear Therapeutics, Inc.	Pear-008.	TX0008935634	2020

Domain Names

peartherapeutics.com
pearthx.com

TRADEMARK

REEL: 008107 FRAME: 0201

RECORDED: 06/22/2023